Table 1

Baseline clinical and biochemical characteristics of the study population

VariablesCAD group (N=82)Control group (N=82)p Value
Age (years)61.9±7.858.5±7.10.003
Male sex, n (%)51 (62.1)47 (57.3)0.289
BMI (kg/m2)27.89±2.227.6±2.10.407
Hypertension, n (%)36 (43.9)22 (26.8)0.034
Diabetes mellitus, n (%)16 (19.5)15 (18.3)1.000
Smoking, n (%)49 (59.8)36 (43.9)0.061
Heart rate (bpm)73.4±10.670.6±9.60.086
Systolic blood pressure (mm Hg)125.1±14.2121.2±12.30.066
Diastolic blood pressure (mm Hg)79±10.575±9.10.022
White cell count (×103/mm3)11.42±4.111.1±5.170.449
Hemoglobin (g/dL)14.34±1.414.05±1.70.231
Platelet (×103/mm3)244.41±48.3234.04±60.30.066
Serum glucose (mg/dL)108.72±28.9109.79±39.70.234
Serum creatinine (mg/dL)0.9±0.20.85±0.20.120
HbA1C (%)5.4±1.15.2±0.90.456
Triglyceride (mg/dL)176.16±129.4171.49±80.30.425
Total cholesterol (mg/dL)182.68±38178.85±42.030.542
LDL-C (mg/dL)112.17±29.5105.15±39.10.197
HDL-C (mg/dL)33.37±7.7239.6±8.52<0.001
LVEF (%)57.57±6.757.13±8.60.983
Galectin-3 (ng/mL)12.96±4.95.52±1.9<0.001
Hs-CRP (mg/L)2.83±1.471.11±0.56<0.001
Gensini score63.37±23.9 (26–123)
Number of diseased vessels
 082 (100%)
 137 (45.1%)
 230 (36.6%)
 315 (18.3%)
Location of stenosis
 LMCA4 (4.9%)
 LAD51 (62.2%)
 LCx35 (42.7%)
 RCA41 (50%)
Medical treatments
 ACE inhibitor/ARB, n (%)22 (26.8)19 (23.2)0.718
 B-blocker, n (%)15 (18.3)11 (13.4)0.521
 Statin, n (%)11 (13.4)9 (11)0.811
 ASA21 (25.6)16 (19.5)0.231
  • ARB, angiotensin receptor blocker; ASA, acetylsalicylic acid; BMI, body mass index; CAD, coronary artery disease; HbA1C, glycated haemoglobin HDL-C, high density lipoprotein cholesterol; Hs-CRP, high sensitive C reactive protein; LAD, left anterior descending coronary artery; LCx left circumflex coronary artery; LDL, low density lipoprotein cholesterol; LMCA, left main coronary artery; LVEF, left ventricular ejection fraction; RCA, right coronary artery.